Eagle Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $78.1M | Sell |
621,363
-58,671
| -9% | -$7.38M | 0.4% | 90 |
|
|
2024
Q2 | $95.3M | Sell |
680,034
-33,491
| -5% | -$4.69M | 0.51% | 75 |
|
|
2024
Q1 | $101M | Sell |
713,525
-14,828
| -2% | -$2.1M | 0.51% | 71 |
|
|
2023
Q4 | $96M | Buy |
728,353
+1,074
| +0.1% | +$142K | 0.51% | 73 |
|
|
2023
Q3 | $81.8M | Buy |
727,279
+489
| +0.1% | +$55K | 0.48% | 82 |
|
|
2023
Q2 | $68.5M | Buy |
726,790
+448,619
| +161% | +$42.3M | 0.38% | 101 |
|
|
2023
Q1 | $28.2M | Sell |
278,171
-314
| -0.1% | -$31.8K | 0.16% | 146 |
|
|
2022
Q4 | $33.4M | Buy |
+278,485
| New | +$33.4M | 0.21% | 138 |
|
|
2016
Q4 | – | Sell |
-914,500
| Closed | -$46.3M | – | 654 |
|
|
2016
Q3 | $46.3M | Sell |
914,500
-27,153
| -3% | -$1.38M | 0.31% | 99 |
|
|
2016
Q2 | $42.8M | Sell |
941,653
-77,564
| -8% | -$3.53M | 0.3% | 109 |
|
|
2016
Q1 | $40.3M | Sell |
1,019,217
-83,863
| -8% | -$3.32M | 0.28% | 115 |
|
|
2015
Q4 | $62.4M | Sell |
1,103,080
-9,052
| -0.8% | -$512K | 0.42% | 77 |
|
|
2015
Q3 | $44.3M | Sell |
1,112,132
-213,937
| -16% | -$8.51M | 0.3% | 112 |
|
|
2015
Q2 | $63.3M | Buy |
1,326,069
+27,635
| +2% | +$1.32M | 0.36% | 101 |
|
|
2015
Q1 | $51.6M | Buy |
+1,298,434
| New | +$51.6M | 0.3% | 127 |
|